Choosing between a daily tablet and a weekly injection of the same molecule is a real decision with real price and supply differences attached, and this desk has covered the format question in the tablet usually costs more. This analysis asks whether the tablet gives anything up on results [1].
The conclusion is that it does not, across percentage weight change, the proportions reaching 5%, 10%, 15% and 20% loss, cardiometabolic measures and quality of life. Small numerical advantages went in both directions depending on the endpoint, and safety profiles were broadly comparable.
The authors note that the difference sits well below the FDA’s 5% threshold for clinical relevance, and that framing is worth understanding precisely. It says a difference of this size would not be considered clinically meaningful — not that a difference has been ruled out. Those are separate statements, and the second one would need a differently designed study.
One question the abstract leaves open is funding. Both products are made by the same manufacturer, which means an equivalence finding is commercially convenient in either direction — it protects the injection’s position while making the tablet easier to launch. The abstract does not state who paid, so the honest position is that the question is unanswered rather than answered either way.
For a reader the practical reading is reasonably comfortable. On the best available evidence, which is indirect, the oral and injected forms of this drug do about the same thing, so the decision can rest on price, supply, whether you can take a tablet on an empty stomach, and whether needles deter you. What each format actually costs across the market is in what a GLP-1 actually costs, the dose distinction in oral dose against injection, and how sellers price the two in oral against injection, same seller.